Fig. 1.

Exo2 blocks ERK1/2 activity and inhibits proliferation in prostate cancer cells. a DU145 and PC3 cells were treated with 20 μM of the indicated Arf1 inhibitors for 24 h, and cell lysates were collected for Western blot with the indicated antibodies. b, c DU145 and PC3 cells were treated with the indicated concentrations of Exo2 for 24 h (b) or 50 μM Exo2 for the indicated times (c), and cell lysates were collected for Western blot with the indicated antibodies. d Prostate cancer cell lines DU145, PC3, 22Rv1 and LNCaP were treated with the indicated concentrations of Exo2 for 72 h, and cell proliferation was determined by MTS. e DU145 and PC3 cells were treated with the indicated concentrations of Exo2 for 24 h, and GGA3-PBD agarose beads were used to pull down the GTP-bound Arf1 and Western blot was used to determine the indicated protein levels.*p < 0.05; **p < 0.01